JCT  Vol.3 No.1 , February 2012
Organ Preservation in Bilharzial Bladder Cancer in Egypt: Single Institutional Experience
ABSTRACT
Background: Phase II study was conducted to evaluate bladder preservation protocol in Bilharzial and non Bilharzial invasive transitional cell carcinoma (TCC) bladder cancer using gemcitabine and conformal radiotherapy (RT). Methods: 30 TCC patients with good performance status and renal function subjected to maximum trans-urethral resection of bladder tumor (TURBT). Patients received 66 Gy/33 fractions/6.5 weeks with weekly gemcitabine 125 mg/m2. Evaluation was done after one month with cystoscopy and CT/MRI pelvis. Patients who had complete remission (CR) subjected for follow up and patients who had invasive bladder tumor subjected to radical cystectomy. Results: 24 patients had CR after one month evaluation. Stage 2 tumor, low grade, non Bilharzial and maximum TUR were the only prognostic factors. The treatment schedule was tolerable and was associated with infrequent incidence of moderate toxicity that was easily controlled without interruption of RT. Cystectomy free survival was 88% at a median follow up for 2 years. Conclusions: Gemcitabine and conformal RT after TURBT treatment could be an effective way to achieve a high response rate in the treatment of invasive TCC of the bladder with good tolerance. Organ preservation in Bilharzial bladder is still possible.

Cite this paper
H. Abbas, M. Aboziada, M. Abdalwanis, M. El-Gmal, A. Mokhtar, M. Abo-Almagd, F. Amr and A. Elyamany, "Organ Preservation in Bilharzial Bladder Cancer in Egypt: Single Institutional Experience," Journal of Cancer Therapy, Vol. 3 No. 1, 2012, pp. 57-63. doi: 10.4236/jct.2012.31008.
References
[1]   G. M. Nazli, M. M. El Bolking and H. M. Khaled, “Bladder Cancer in Africa: Update,” Seminars in Oncology, Vol. 28, No. 2, 2001, pp. 174-178. doi:/10.1016/S0093-7754(01)90089-2

[2]   A. Faysal, M. D. Yafi and M. D. Wassim Kassouf, “Radical Cystectomy Is the Treatment of Choice for Invasive Bladder Cancer,” Canadian Urological Association Journal, Vol. 3, No. 5, 2009, pp. 409-412.

[3]   D. Raghavan and R. Huben, “Management of Bladder Cancer,” Current Problems in Cancer, Vol. 19, No. 1, 1995, pp. 3-63. doi:/10.1016/S0147-0272(07)80002-X

[4]   A. Choudhury, R. Swindell, J. P. Logue, P. Anthony Elliott, J. E. Livsey, M. Wise, P. Symonds, J. P. Wylie, V. Ramani, V. Sangar, et al., “Phase II Study of Conformal Hypofractionated Radiotherapy with Concurrent Gemcitabine in Muscle-Invasive Bladder Cancer,” Journal of Clinical Oncology, Vol. 29, No. 6, 2011, pp. 733-738. doi:/10.1200/JCO.2010.31.5721

[5]   S. Kotwal, A. Choudhury, C. Johnston, et al., “Similar Treatment Outcomes for Radical Cystectomy and Radical Radiotherapy in Invasive Bladder Cancer Treated at a United Kingdom Specialist Treatment Center,” International Journal of Radiation Oncology Biology Physics, Vol. 70, No. 2, 2008, pp. 456-463. doi:/10.1016/j.ijrobp.2007.06.030

[6]   J. Dunst, R. Saur, K. M. Schrott, et al., “Organ-Sparing Treatment of Advanced Bladder Cancer: A 10-Year Experience,” International Journal of Radiation Oncology Biology Physics, Vol. 30, No. 2, 1994, pp. 261-266.

[7]   D. S. Kaufman, W. U. Shipley, P. P. Griffin, N. M. He- ney, A. F. Althausen and J. T. Efird, “Selective Preservation by Combination Treatment of Invasive Bladder Cancer,” The New England Journal of Medicine, Vol. 329, No. 19, 1993, pp. 1377-1382. doi:/10.1056/NEJM199311043291903

[8]   M. Housset, C. Maulard, Y. C. Chretien, et al., “Combined Radiation and Chemotherapy for Invasive Transitional-Cell Carcinoma of the Bladder: A Prospective Study,” Journal of Clinical Oncology, Vol. 11, No. 11, 1993, pp. 2150-2157.

[9]   L. Eapen, D. Stewart, C. Danjoux, P. Genest, N. Futter, et al., “Intraarterial Cisplatin and Concurrent Radiation for Locally Advanced Bladder Cancer,” Journal of Clinical Oncology, Vol. 7, No. 2, 1989, pp. 230-235. doi:/10.1016/j.eururo.2009.01.002

[10]   A. Stenzl, N. Cowan, M. De Santis, et al., “The Updated EAU Guidelines on Muscle-Invasive and Metastatic Bladder Cancer,” European Urology, Vol. 55, No. 4, 2009, pp. 815-825.

[11]   H. Von der Maase, L. Sengelov, J. Roberts, et al., “Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine plus Cisplatin, with Methotrexate, Vinblastine, Doxorubicin, plus Cisplatin in Patients with Bladder Cancer,” Journal of Clinical Oncology, Vol. 23, No. 2, 2005, pp. 4602-4608. doi:/10.1200/JCO.2005.07.757

[12]   V. K. Sangar, C. A. McBain, J. Lyons, et al., “Phase I Study of Conformal Radiotherapy with Concurrent Gemcitabine in Locally Advanced Bladder Cancer,” International Journal of Radiation Oncology Biology Physics, Vol. 61, No. 2, 2005, pp. 420-425. doi:/10.1016/j.ijrobp.2004.05.074

[13]   V. K. Sangar, R. Cowan, G. P. Margison, et al., “An Evaluation of Gemcitabines Differential Radiosensitising Effect in Related Bladder Cancer Cell Lines,” British Journal of Cancer, Vol. 90, No. 2, 2004, pp. 542-548. doi:/10.1038/sj.bjc.6601538

[14]   B. Pauwels, A. E. C. Korst, F. Lardon and J. B. Vermorken, “Combined Modality Therapy of Gemcitabine and Radiation,” The Oncologist, Vol. 10, No. 1, 2005, pp. 34-51. doi:/10.1634/theoncologist.10-1-34

[15]   V. K. Sangar, C. A. McBain, J. Lyons, V. A. Ramani, J. P. Logue, J. P. Wylie, N. W. Clarke and R. A. Cowan, “Phase I Study of Conformal Radiotherapy with Concurrent Gemcitabine in Locally Advanced Bladder Cancer,” International Journal of Radiation Oncology Biology Physics, Vol. 62, No. 2, 2005, pp. 420-425. doi:/10.1016/j.ijrobp.2004.05.074

[16]   E. L. Kaplan and P. Meier, “Nonparametric Estimation from Incomplete Observations,” Journal of American Statistical Association, Vol. 53, No. 282, 1958, pp. 457-481. doi:/10.2307/2281868

[17]   Common Toxicity Criteria, Version 3. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf

[18]   M. A. Aboziada, H. M. Hamza and A. M. Abdlrahem, “Initial Results of Bladder Preserving Approach by Chemo-Radiotherapy in Patients with Muscle Invading Transitional Cell Carcinoma,” Journal of the Egyptian National Cancer Institute, Vol. 21, No. 2, 2009, pp. 167-174.

[19]   H. Shawky and G. El-Deen, “Initial Results of Retrospective Study: Preoperative Transurethral Excision plus Chemotherapy and Radiation Therapy and Trial of Bladder Preservation,” Journal of the Egyptian National Cancer Institute, Vol. 19, No. 2, 2007, pp. 133-146.

[20]   W. U. Shipley, D. S. Kaufman, E. Zehr, et al., “Selective Bladder Preservation by Combined Modality Protocol Treatment: Long-Term Outcomes of 190 Patients with Invasive Bladder Cancer,” Urology, Vol. 60, No. 1, 2002, pp. 62-67. doi:/10.1016/S0090-4295(02)01650-3

[21]   R. Sauer, S. Birkenhake, R. Kuhn, C. Wittekind, K. M. Schrott and P. Martus, “Efficacy of Radiochemotherapy with Platin Derivatives Compared to Radiotherapy Alone in Organ-Sparing Treatment of Bladder Cancer,” International Journal of Radiation Oncology Biology Physics, Vol. 40, No. 1, 1998, pp. 121-127. doi:/10.1016/S0360-3016(97)00579-8

[22]   A. Zapatero, C. Martin de Vidales, R. Arellano, et al., “Updated Results of Bladder Sparing Trimodality Approach for Invasive Bladder Cancer,” Urologic Oncology: Seminars and Original Investigations, Vol. 28, No. 4, 2009, pp. 368-374.

[23]   W. U. Shipley, K. A. Winter, D. S. Kaufman, et al., “Phase III Trial of Neoadjuvant Chemotherapy in Patients with Invasive Bladder Cancer Treated with Selective Bladder Preservation by Combined Radiation Therapy and Chemotherapy: Initial Results of Radiation Therapy Oncology Group 89-03,” Journal of Clinical Oncology, Vol. 16, No. 11, 1998, pp. 3576-3583.

[24]   D. S. Kaufman, K. A. Winter, W. U. Shipley, et al., “Phase I-II RTOG Study (99-06) of Patients With Muscle-Invasive Bladder Cancer Undergoing Transurethral Surgery, Paclitaxel, Cisplatin, and Twice-daily Radiotherapy Followed by Selective Bladder Preservation or Radical Cystectomy and Adjuvant Chemotherapy,” Urology, Vol. 73, No. 4, 2009, pp. 833-837. doi:/10.1016/j.urology.2008.09.036

[25]   F. Arias, M. A. Dominguez, E. Martinez, et al., “Chemoradiotherapy for Muscle Invading Bladder Carcinoma. Final Report of a Single Institutional Organ-Sparing Program,” International Journal of Radiation Oncology Biology Physics, Vol. 47, No. 2, 2000, pp. 373-378. doi:/10.1016/S0360-3016(00)00444-2

[26]   C. Rodel, G. G. Grabenbauer, R. Kuhn, et al., “Organ Preservation in Patients with Invasive Bladder Cancer: Initial Results of an Intensified Protocol of Transurethral Surgery and Radiation Therapy plus Concurrent Cisplatin and 5-Fluorouracil,” International Journal of Radiation Oncology Biology Physics, Vol. 52, No. 2, 2002, pp. 1303-1309. doi:/10.1016/S0360-3016(01)02771-7

[27]   E. Kent, H. Sandler, J. Montie, et al., “Combined-Modality Therapy with Gemcitabine and Radiotherapy as a Bladder Preservation Strategy: Results of a Phase I Trial,” Journal of Clinical Oncology, Vol. 22, No. 13, 2004, pp. 2540-2545. doi:/10.1200/JCO.2004.10.070

 
 
Top